Stay informed with the latest litigation news. Explore now

IP Verse

Samsung Bioepis competitive analysis

Latest publications and patents of Samsung Bioepis New

Explore the latest publications and patents granted to Samsung Bioepis, showcasing their recent innovations and technological advancements.

Last updated on: Sep 11, 2025

Publication Number	Publication Date	Title	Legal Status
Get instant update for new patents of Samsung Bioepis
EP3036320	Apr 3, 2024	Control Of Protein Glycosylation By Culture Medium Supplementation And Cell Culture Process Parameters	Patent Maintained As Amended
EP3122869	Aug 10, 2022	Methods For Overcoming Glutamine Deprivation During Mammalian Cell Culture	Patent Maintained As Amended

Latest oppositions filed by Samsung Bioepis

Explore patent oppositions filed by Samsung Bioepis against competitors, revealing strategic technology disputes and market positioning.

Last updated on: Sep 18, 2025

Patent Number	Title	Applicant	Opposition Date
Get instant updates on new opposition filings by the company
EP3167888	Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement	ALEXION PHARMACEUTICALS	May 2, 2024
EP3883606	Safe And Effective Method Of Treating Ulcerative Colitis With Anti-Il12/Il23 Antibody	JANSSEN BIOTECH	Feb 5, 2024
EP2894165	Methods And Compositions For Treating Complement-Associated Disorders	ALEXION PHARMACEUTICALS	Oct 4, 2023
EP3403646	Liquid Pharmaceutical Composition	FRESENIUS KABI DEUTSCHLAND	Oct 5, 2022
EP3145488	Liquid Pharmaceutical Composition	ARES TRADING	Apr 22, 2021
EP3145488	Liquid Pharmaceutical Composition	ARES TRADING	Jul 22, 2020
EP3212667	Pharmaceutical Anti-Tnf-Alpha Antibody Formulation	RICHTER GEDEON NYRT	Dec 12, 2019
EP3212667	Pharmaceutical Anti-Tnf-Alpha Antibody Formulation	RICHTER GEDEON NYRT	Jun 19, 2019
EP3148510	Liquid Pharmaceutical Composition	ARES TRADING	Mar 26, 2019

Latest patents of Samsung Bioepis opposed by its competitors

Explore Samsung Bioepis's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 18, 2025

Patent Number	Grant Date	Title	Total Oppositions
EP3036320	Apr 3, 2024	Control Of Protein Glycosylation By Culture Medium Supplementation And Cell Culture Process Parameters	1
EP3122869	Aug 10, 2022	Methods For Overcoming Glutamine Deprivation During Mammalian Cell Culture	1

Latest PTAB cases involving Samsung Bioepis New

Discover the latest PTAB cases involving Samsung Bioepis, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 17, 2025

Proceeding Number	Filing Date	Petitioner	Respondent	Status
Get alerts for PTAB Cases involving Samsung Bioepis
IPR2025-00176	Nov 20, 2024	SAMSUNG BIOEPIS	REGENERON PHARMACEUTICALS	Institution Denied
IPR2023-01312	Aug 18, 2023	SAMSUNG BIOEPIS	REGENERON PHARMACEUTICALS	Terminated-Adverse Judgment
IPR2023-01103	Jun 21, 2023	SAMSUNG BIOEPIS	JANSSEN BIOTECH	Terminated-Settled
IPR2023-01070	Jun 16, 2023	SAMSUNG BIOEPIS	ALEXION PHARMACEUTICALS	Terminated-Settled
IPR2023-01069	Jun 16, 2023	SAMSUNG BIOEPIS	ALEXION PHARMACEUTICALS	Terminated-Settled
IPR2023-00999	May 31, 2023	SAMSUNG BIOEPIS	ALEXION PHARMACEUTICALS	Terminated-Settled
IPR2023-00998	May 31, 2023	SAMSUNG BIOEPIS	ALEXION PHARMACEUTICALS	Terminated-Settled
IPR2023-00933	May 18, 2023	SAMSUNG BIOEPIS	ALEXION PHARMACEUTICALS	Terminated-Settled
IPR2023-00884	Apr 27, 2023	SAMSUNG BIOEPIS	REGENERON PHARMACEUTICALS	Terminated-Adverse Judgment
IPR2023-00739	Mar 26, 2023	SAMSUNG BIOEPIS	REGENERON PHARMACEUTICALS	Terminated-Adverse Judgment

Top competitors of Samsung Bioepis

Top competitors of Samsung Bioepis based on patent oppositions.

FRESENIUS KABI DEUTSCHLAND

ARES TRADING

ABG LAW